1. Search Result
Search Result
Results for "

Hexokinase 2

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134929

    BNBZ; Hexokinase 2 inhibitor 1

    Hexokinase Apoptosis Cancer
    Benitrobenrazide (BNBZ) is the orally active inhibitor for hexokinase 2 with an IC50 of 0.53 µM. Benitrobenrazide causes DNA damage, and exhibits antitumor effect .
    Benitrobenrazide
  • HY-P10108

    Hxk2VBD peptide, cell-permeable

    Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-W000133

    Amipaque

    Hexokinase Neurological Disease
    Metrizamide (Amipaque) is used as the contrast medium for angiography in neuroradiological investigations . Metrizamide inhibits human brain hexokinase .
    Metrizamide
  • HY-155008
    PROTAC HK2 Degrader-1
    2 Publications Verification

    PROTACs Hexokinase Cancer
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
    PROTAC HK2 Degrader-1
  • HY-168717

    Hexokinase Microtubule/Tubulin Reactive Oxygen Species Cancer
    Antitumor agent-190 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC50 value of 0.764 μM against MD-MBA-231 cells. Antitumor agent-190 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle .
    Antitumor agent-190

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: